Discovery of tight junction modulators: significance for drug development and delivery

Drug Discovery Today

Volumn 13, Issue 5-6, 2008, Pages 261-267

  Johnson, Paul H ^a   Frank, Diane ^a   Costantino, Henry R ^a  

^a Nastech Pharmaceutical Company Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O HEXADECYL 2 AZELAOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 O OCTADECYL 2 O METHYLGLYCEROL 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 (5' OXO VALEROYL) SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 (9' OXO NONANOYL) SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 AZELAOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 GLUTAROYL SN GLYCERO 3 PHOSPHOCHOLINE; ALANYLALANYLALANYLASPARTYLPROLYLTYROSYLALANYLGLUTAMINYL TRYPTOPHYLLEUCYLGLUTAMINYLSERYLMETHIONYLGLYCYLPROLYLHISTIDYLSERYL GLYCYLARGINYLPROLYLPROLYLPROLYLARGININE; ASPARAGINYLLEUCYLTYROSYLISOLEUCYLGLUTAMINYLTRYPTOPHYLLEUCYL LYSYLASPARTYLGLYCYLGLYCYLPROLYLSERYLSERYLGLYCYLARGINYLPROLYLPROLYLPROLYLSERINE; CALCITONIN; CHELATING AGENT; CHOLERA TOXIN; DEXTRO LACTOSYL BETA 1' DEXTRO ERYTHROSPHINGOSINE(LACTOSYL BETA SPHINGOSINE); EGTAZIC ACID; ETHER LIPID; GALANTAMINE; GAMMA INTERFERON; GLUCOSIDE; GLUCOSYL SPHINGOSINE; LIPID; PARATHYROID HORMONE[1-34]; PEPTIDE LIBRARY; PHENYLALANYLASPARTYLPHENYLALANYLTRYPTOPHYLISOLEUCYLTHREONYLPROLINE; PN 159; PROTEIN DERIVATIVE; PYY 3 36; SALCATONIN; SPHINGOSINE DERIVATIVE; TIGHT JUNCTION MODULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

CELL FUNCTION; CELL JUNCTION; CELL STRESS; CELL VIABILITY; CYTOSKELETON; DESMOSOME; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM; EPITHELIUM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; MOLECULAR LIBRARY; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; REVIEW; TIGHT JUNCTION;

EID: 40649116006     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.10.023     Document Type: Review

References (50)

1. S. Tsukita Multifunctional strands in tight junctions Nat. Rev. Mol. Cell Biol. 2 2001 285 293
2. O.W. Blaschuk T.M. Rowlands Plasma membrane components of adherens junctions Mol. Membr. Biol. 19 2002 75 80
3. K. Matter M.S. Balda Signalling to and from tight junctions Nat. Rev. Mol. Cell Biol. 4 2003 225 236
4. A.I. Ivanov Endocytosis of the apical junctional complex: mechanisms and possible roles in regulation of epithelial barriers Bioessays 27 2005 356 365
5. A.I. Ivanov Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment Mol. Biol. Cell 15 2004 176 188
6. J.M. Mullin Keynote review: epithelial and endothelial barriers in human disease Drug Discov. Today 10 2005 395 408
7. M. Cereijido New diseases derived or associated with the tight junction Arch. Med. Res. 38 2007 465 478
8. M. Utech Mechanism of INF-γ induced endocytosis of tight junction proteins: myosin II dependent vacuolarization of the apical plasma membrane Mol. Biol. Cell 16 2005 5040 5052
9. J.P. Segain Rho kinase blockage prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis Gastroentology 124 2003 1180 1187
10. K.M. McCarthy Occludin is a functional component of the tight junction J. Cell Sci. 109 1996 2287 2298
11. A.B. Singh R.C. Harris Epidermal growth factor receptor activation differentially regulates Claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells J. Biol. Chem. 279 2004 3543 3552
12. D. Flores-Benitez Control of tight junctional sealing: role of the epidermal growth factor Am. J. Physiol. Renal. Physiol. 292 2007 F828 F836
13. J. Berkes Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation Gut 52 2003 439 451
14. A. Fasano Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions Proc. Natl. Acad. Sci. U. S. A. 88 1991 5242 5246
15. A. Fasano Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin Ann. N. Y. Acad. Sci. 915 2000 214 222
16. W. Wang Human zonulin, a potential modulator of intestinal tight junctions J. Cell Sci. 113 Pt 24 2000 4435 4440
17. M. Di Pierro Zonula occludens toxin structure–function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain J. Biol. Chem. 276 2001 19160 19165
18. K.G. Dickman Rotavirus alters paracellular permeability and energy metabolism in caco-2 cells Am. J. Physiol. Gastrointest. Liver Physiol. 279 2000 G757 G766
19. P. Nava The rotavirus surface protein VP8 modulates the gate and fence function of epithelial cells J. Cell Sci. 117 2004 5509 5519
20. P.H. Johnson S.C. Quay Advances in nasal drug delivery through tight junction technology Expert Opin. Drug Deliv. 2 2005 281 298
21. G.P. Smith Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface Science 228 1985 1315 1317
22. H.B. Lowman Bacteriophage display and discovery of peptide leads for drug development Annu. Rev. Biophys. Biomol. Struct. 26 1997 401 424
23. Herman, R.E. et al . (2007) Phage display screening of epithelial cell monolayers treated with EGTA: identification of peptide FDFWITP that modulates tight junction activity. J. Biomol. Screen. [Epub ahead of print]
24. R.E. Herman The TRP cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7 J. Biol. Chem. 282 2007 9812 9824
25. J.W. Neidigh Designing a 20-residue protein Nat. Struct. Biol. 9 2002 425 430
26. J.W. Neidigh Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states Biochemistry 40 2001 13188 13200
27. L. Qiu Smaller and faster: the 20-residue Trp-cage protein folds in 4 micros J. Am. Chem. Soc. 124 2002 12952 12953
28. T.R. Kumar Novel delivery technologies for protein and peptide therapeutics Curr. Pharm. Biotechnol. 7 2006 261 276
29. D.K. Malik Recent advances in protein and peptide drug delivery systems Curr. Drug Deliv. 4 2007 141 151
30. M. Morishita N.A. Peppas Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11 2006 905 910
31. V. Sinha Oral colon-specific drug delivery of protein and peptide drugs Crit. Rev. Ther. Drug Carrier Syst. 24 2007 63 92
32. M.R. Prausintz Current status and future potential of transdermal drug delivery Nat. Rev. Drug Discov. 3 2004 115 124
33. A. Nanda Current developments using emerging transdermal technologies in physical enhancement methods Curr. Drug Deliv. 3 2006 233 242
34. J.D. Smart Buccal drug delivery Expert Opin. Drug Deliv. 2 2005 507 517
35. C.L. Leach Inhalation aspects of therapeutic aerosols Toxicol. Pathol. 35 2007 23 26
36. J.S. Patton P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74
37. H.R. Costantino Pharmacokinetic attributes of intranasal delivery: case studies and new opportunities OnDrugDelivery 3 2005 8 11
38. H.R. Costantino Intranasal delivery: physicochemical and therapeutic aspects Int. J. Pharm. 337 2007 1 24
39. V.D. Romeo Optimization of systemic nasal drug delivery with pharmaceutical excipients Adv. Drug. Deliv. Rev. 29 1998 117 133
40. A. Kays Leonard In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo Int. J. Pharm. 225 2007 138 146
41. U.S. Food and Drug Administration (2005) Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients or http://www.fda.gov/cber/gdlns/dvpexcp.htm
42. U.S. Food and Drug Administration (2006) Guidance for Industry: ICH Q8 Pharmaceutical Development or http://www.fda.gov/cber/gdlns/ichq8pharm.htm
43. U.S. Food and Drug Administration (2006) Guidance for Industry: ICH Q9 Quality Risk Management or http://www.fda.gov/cber/gdlns/ichq9risk.htm
44. J.O. Henck S.R. Byrn Designing a molecular delivery system within a preclinical timeframe Drug Discov. Today 12 2007 189 199
45. Chen-Quay, S.C., Eiting, K.T., Li, A.W-A., Lamharzi, N., Quay, S.C. Identification of tight junction modulating lipids, submitted for publication
46. F. Ahsan Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-) Eur. J. Pharm. Sci. 20 2003 27 34
47. J.J. Arnold Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells J. Pharm. Sci. 93 2004 2205 2213
48. S.C. Chen Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery J. Pharm. Sci. 95 2006 1364 1371
49. A. Kays Leonard Development of a novel high-concentration galantamine formulation suitable for intranasal delivery J. Pharm. Sci. 94 2005 1736 1746
50. N.V. Chemuturi Comparison of human tracheal/bronchial epithelial cell culture and bovine nasal respiratory explants for nasal drug transport studies J. Pharm. Sci. 94 2005 1976 1985